Regeneron stock jumped Tuesday after the biotech giant topped Wall Street's December-quarter calls on the back of its cancer drug Libtayo. The company also announced a dividend for the first time.

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

The EC approved Libtayo – a fully human monoclonal antibody ... therapeutics for the treatment of cancer. Meanwhile, another company focused on advanced cervical cancer is Nykode Therapeutics ...

Libtayo was first approved in 2018 ... This is an increase from the ORR of 29% the company shared in May and includes two responses that were confirmed after an initial data analysis.

Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with ...

(RTTNews) - Immuneering Corporation (IMRX), a clinical-stage oncology company, Thursday said it ... in combination with Regeneron's immunotherapy drug Libtayo in patients with advanced non-small ...

The agreement was signed in a letter of intent March 3 to set the groundwork for whether government health programs in different provinces and territories will cover the drug's cost for patients, ...

Libtayo plays a crucial role in leukemia treatment ... Learn More About The Business Research Company The Business Research Company provides in-depth research and insights through a vast ...

Arm 1 will administer Libtayo on day 5. The Company plans to enroll an additional 100 patients for the registration phase of the trial. MAIA expects to conduct the trials in the U.S. and select ...

Regeneron UK Limited has announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo (cemiplimab) for use on the National Health Service. This approval is for second-line monotherapy ...

Valued at $73.8 billion by market cap, the company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. Companies worth $ ...